Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Colorcon
McKinsey
Moodys
Johnson and Johnson

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Plerixafor - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for plerixafor and what is the scope of patent protection?

Plerixafor is the generic ingredient in one branded drug marketed by Genzyme and is included in one NDA. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Plerixafor has forty-one patent family members in twenty-six countries.

There are seven drug master file entries for plerixafor. One supplier is listed for this compound.

Recent Clinical Trials for plerixafor

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Reproductive Medicine Associates of New JerseyN/A
European Myeloma NetworkPhase 2
EMN Research ItalyPhase 2

See all plerixafor clinical trials

Recent Litigation for plerixafor

Identify potential future generic entrants

District Court Litigation
Case NameDate
Genzyme Corporation v. Fresenius Kabi USA, LLC2018-12-06
Genzyme Corporation v. Gland Pharma Limited2018-07-19
Genzyme Corporation v. Zydus Pharmaceuticals (USA) Inc.2016-06-29

See all plerixafor litigation

Pharmacology for plerixafor
Synonyms for plerixafor
078P461
1-({4-[(1,4,8,11-tetraazacyclotetradecan-1-yl)methyl]phenyl}methyl)-1,4,8,11-tetraazacyclotetradecane
1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
1-{[4-(1,4,8,11-tetraazacyclotetradecan-1-ylmethyl)phenyl]methyl}-1,4,8,11-tetraazacyclotetradecane
1,1'-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane
1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]
1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA)
1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin( HHA)
1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}
1,1''''-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}
1,1'[1,4-phenylene-bis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
1,4-Bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene
1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane
1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane(8HBr.2H2O)
11-{4-[4,8, 11-1,4,8,11tetraaza-cyclotetradec-1-ylmethyl]-benzyl}-1,4,8,11tetraaza-cyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester
11''''-xylyl bis-1,4,8,11-tetraazacyclotetradecane
110078-46-1
4CA-1029
A25446
A809618
AB0009909
AB01566900_01
AB1008451
AC-26837
AC1L22ET
AJ-81365
AK-41732
AKOS005266706
Amd 3100
AMD-3100
AMD3100
AMD3100 octahydrochloride
AN-436
ANW-73610
AOB5591
AS-42504
BC623053
BCP02337
BCPP000104
BDBM50035696
bicyclam JM-2987
BRD-K33240821-367-01-8
C28H54N8
CHEBI:125354
CHEMBL18442
CS-0451
CTK8C4952
D08971
DB06809
EX-A1762
FT-0660392
GNA & AMD-3100
GTPL844
HHA & AMD-3100
HY-10046
I14-9461
J-503718
JKL 169
JM 2987
JM 3100
JM 3100, AMD3100
JM-3100
JM3100
KS-00000OBY
L000104
LS-187299
MolPort-009-019-417
Mozobil
Mozobil (TN)
NCGC00165722-01
NCGC00165722-02
plerixafor (amd3100)
Plerixafor (JAN/USAN/INN)
Plerixafor [USAN:INN:BAN]
Plerixafor-d4 (deuterated)
Plerixafor(AMD3100)
RL00426
S-7677
s8030
S915P5499N
SC-21932
SCHEMBL19038
SDZ SID 791
SID791
SR-01000941593
SR-01000941593-1
ST2414835
TC-162355
UNII-S915P5499N
YIQPUIGJQJDJOS-UHFFFAOYSA-N
Z2196779619
ZINC22443609
Paragraph IV (Patent) Challenges for PLERIXAFOR
Tradename Dosage Ingredient NDA Submissiondate
MOZOBIL SOLUTION;SUBCUTANEOUS plerixafor 022311 2012-12-17

US Patents and Regulatory Information for plerixafor

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 RX Yes Yes   Start Trial   Start Trial   Start Trial
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for plerixafor

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1411918 SPC/GB12/031 United Kingdom   Start Trial PRODUCT NAME: PLERIXAFOR OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR METAL COMPLEX THEREOF; REGISTERED: UK EU/1/09/537/001 20090804
1411918 215 5011-2012 Slovakia   Start Trial PRODUCT NAME: PLERIXAFOR; REGISTRATION NO/DATE: EU/1/09/537/001 20090804
0619813 SPC/GB10/004 United Kingdom   Start Trial PRODUCT NAME: PLERIXAFOR IN ALL FORMS PROTECTED BY THE BASIC PATENT; REGISTERED: UK EU/1/09/537/001 20090731; REASON FOR LAPSE: SURRENDERED
0619813 10C0002 France   Start Trial PRODUCT NAME: PLERIXAFOR SOUS TOUTES SES FORMES, EN PARTICULIER SES SELS D'ADDITION AVEC UN ACIDE NON TOXIQUE OU SES COMPLEXES AVEC UN METAL; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
1411918 C300537 Netherlands   Start Trial PRODUCT NAME: PLERIXAFOR IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VORM; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
1411918 2012C/027 Belgium   Start Trial PRODUCT NAME: PLERIXAFOR SOUS TOUTES FORMES COUVERTES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/09/537/001 20090804
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Harvard Business School
Dow
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.